Yoon Jimi, Park Donghwa, Kim Chiyeon
Department of Dermatology, Gyeongsang National University Hospital, Jinju, Korea.
Department of Dermatology, Gyeongsang National University Hospital, Jinju, Korea. ; Institute of Health Science, Gyeongsang National University School of Medicine, Jinju, Korea.
Ann Dermatol. 2013 Nov;25(4):493-5. doi: 10.5021/ad.2013.25.4.493. Epub 2013 Nov 30.
Entecavir (Baraclude®, Bristol-Myers Squibb) is a potent and selective antiviral agent that has demonstrated efficacy in patients with chronic hepatitis B. The most frequent adverse events attributed to entecavir include increased alanine aminotransferase, upper respiratory tract infection, headache, abdominal pain, cough, pyrexia, fatigue, and diarrhea. Although quite a few randomized double-blind studies including ones investigating adverse events along with these general symptoms have been reported, few cases of cutaneous adverse events have been described in detail. We demonstrate a case of granulomatous drug eruption as a cutaneous adverse event induced by entecavir.
恩替卡韦（博路定®，百时美施贵宝公司）是一种强效且具有选择性的抗病毒药物，已在慢性乙型肝炎患者中显示出疗效。归因于恩替卡韦的最常见不良事件包括丙氨酸转氨酶升高、上呼吸道感染、头痛、腹痛、咳嗽、发热、疲劳和腹泻。尽管已经报道了不少随机双盲研究，包括那些调查这些一般症状以及不良事件的研究，但很少有皮肤不良事件的病例得到详细描述。我们报告一例由恩替卡韦引起的皮肤不良事件——肉芽肿性药疹。
